Corneal diseases are among the most common causes of blindness and visual impairment, with Fuchs endothelial corneal dystrophy (FECD), a gradual swelling and clouding of the cornea, being the most common reason for eventual corneal transplants.
Writing in the March 30 online issue of Nature Communications, researchers at University of California San Diego School of Medicine, with colleagues at Case Western University, Duke University, the National Institutes of Health and elsewhere, have identified three novel genomic loci -- distinct stretches of genetic material on chromosomes -- linked to FECD, which often clusters in families and is roughly 39 percent heritable.
"Previously, there was one known FECD locus. We've expanded that number to four," said the study's first author Natalie A. Afshari, MD, professor of ophthalmology, Stuart Brown MD Chair in Ophthalmology in Memory of Donald Shiley and chief of cornea and refractive surgery at Shiley Eye Institute at UC San Diego Health. "These findings provide a deeper understanding of the pathology of FECD, which in turn will help us develop better therapies for treating or preventing this disabling disease."
The research team conducted a genome-wide association study, an analytical approach in which scientists look for genetic variants in individuals associated with a particular disease. This study involved 1,404 patients with FECD and 2,564 controls of European ancestry.
The results confirmed the known role of the TCF4 gene, but also revealed associations with three other loci: KANK4, LAMC1 and LINC009970/ATPB1. Researchers also found some genomic markers that were more associated by gender, with LAMC1 increasing FECD risk in women while TCF4 increased risk in men.
"While more work must be done to precisely elucidate what these proteins do," said Afshari, "the results suggest they have essential roles in sustaining and maintaining the health of the corneal endothelium. This knowledge improves our understanding of the genetic risk factors for FECD and gives us new therapeutic targets."